Cargando…
Novel vaccine safety issues and areas that would benefit from further research
Vaccine licensure requires a very high safety standard and vaccines routinely used are very safe. Vaccine safety monitoring prelicensure and postlicensure enables continual assessment to ensure the benefits outweigh the risks and, when safety problems arise, they are quickly identified, characterise...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137224/ https://www.ncbi.nlm.nih.gov/pubmed/34011502 http://dx.doi.org/10.1136/bmjgh-2020-003814 |
_version_ | 1783695578835714048 |
---|---|
author | Salmon, Daniel A Lambert, Paul Henri Nohynek, Hanna M Gee, Julianne Parashar, Umesh D Tate, Jacqueline E Wilder-Smith, Annelies Hartigan-Go, Kenneth Y Smith, Peter G Zuber, Patrick Louis F |
author_facet | Salmon, Daniel A Lambert, Paul Henri Nohynek, Hanna M Gee, Julianne Parashar, Umesh D Tate, Jacqueline E Wilder-Smith, Annelies Hartigan-Go, Kenneth Y Smith, Peter G Zuber, Patrick Louis F |
author_sort | Salmon, Daniel A |
collection | PubMed |
description | Vaccine licensure requires a very high safety standard and vaccines routinely used are very safe. Vaccine safety monitoring prelicensure and postlicensure enables continual assessment to ensure the benefits outweigh the risks and, when safety problems arise, they are quickly identified, characterised and further problems prevented when possible. We review five vaccine safety case studies: (1) dengue vaccine and enhanced dengue disease, (2) pandemic influenza vaccine and narcolepsy, (3) rotavirus vaccine and intussusception, (4) human papillomavirus vaccine and postural orthostatic tachycardia syndrome and complex regional pain syndrome, and (5) RTS, S/adjuvant system 01 malaria vaccine and meningitis, cerebral malaria, female mortality and rebound severe malaria. These case studies were selected because they are recent and varied in the vaccine safety challenges they elucidate. Bringing these case studies together, we develop lessons learned that can be useful for addressing some of the potential safety issues that will inevitably arise with new vaccines. |
format | Online Article Text |
id | pubmed-8137224 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-81372242021-06-01 Novel vaccine safety issues and areas that would benefit from further research Salmon, Daniel A Lambert, Paul Henri Nohynek, Hanna M Gee, Julianne Parashar, Umesh D Tate, Jacqueline E Wilder-Smith, Annelies Hartigan-Go, Kenneth Y Smith, Peter G Zuber, Patrick Louis F BMJ Glob Health Analysis Vaccine licensure requires a very high safety standard and vaccines routinely used are very safe. Vaccine safety monitoring prelicensure and postlicensure enables continual assessment to ensure the benefits outweigh the risks and, when safety problems arise, they are quickly identified, characterised and further problems prevented when possible. We review five vaccine safety case studies: (1) dengue vaccine and enhanced dengue disease, (2) pandemic influenza vaccine and narcolepsy, (3) rotavirus vaccine and intussusception, (4) human papillomavirus vaccine and postural orthostatic tachycardia syndrome and complex regional pain syndrome, and (5) RTS, S/adjuvant system 01 malaria vaccine and meningitis, cerebral malaria, female mortality and rebound severe malaria. These case studies were selected because they are recent and varied in the vaccine safety challenges they elucidate. Bringing these case studies together, we develop lessons learned that can be useful for addressing some of the potential safety issues that will inevitably arise with new vaccines. BMJ Publishing Group 2021-05-19 /pmc/articles/PMC8137224/ /pubmed/34011502 http://dx.doi.org/10.1136/bmjgh-2020-003814 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Analysis Salmon, Daniel A Lambert, Paul Henri Nohynek, Hanna M Gee, Julianne Parashar, Umesh D Tate, Jacqueline E Wilder-Smith, Annelies Hartigan-Go, Kenneth Y Smith, Peter G Zuber, Patrick Louis F Novel vaccine safety issues and areas that would benefit from further research |
title | Novel vaccine safety issues and areas that would benefit from further research |
title_full | Novel vaccine safety issues and areas that would benefit from further research |
title_fullStr | Novel vaccine safety issues and areas that would benefit from further research |
title_full_unstemmed | Novel vaccine safety issues and areas that would benefit from further research |
title_short | Novel vaccine safety issues and areas that would benefit from further research |
title_sort | novel vaccine safety issues and areas that would benefit from further research |
topic | Analysis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137224/ https://www.ncbi.nlm.nih.gov/pubmed/34011502 http://dx.doi.org/10.1136/bmjgh-2020-003814 |
work_keys_str_mv | AT salmondaniela novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch AT lambertpaulhenri novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch AT nohynekhannam novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch AT geejulianne novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch AT parasharumeshd novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch AT tatejacquelinee novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch AT wildersmithannelies novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch AT hartigangokennethy novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch AT smithpeterg novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch AT zuberpatricklouisf novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch |